Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.

Anastasilakis, A D; Polyzos, S A; Gkiomisi, A; Saridakis, Z G; Digkas, D; Bisbinas, I; Sakellariou, G T; Papatheodorou, A; Kokkoris, P; Makras, P

Anastasilakis, A D; Polyzos, S A; Gkiomisi, A; Saridakis, Z G; Digkas, D; Bisbinas, I; Sakellariou, G T; Papatheodorou, A; Kokkoris, P; Makras, P.

Afiliación

Anastasilakis AD; Department of Endocrinology, 424 General Military Hospital, Ring Road, 564 29 N.Efkarpia, Thessaloniki, Greece. anastath@endo.gr.
Polyzos SA; Second Medical Clinic, Department of Medicine, Ippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Gkiomisi A; Department of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece.
Saridakis ZG; Hellenic Military School of Medicine, Thessaloniki, Greece.
Digkas D; Hellenic Military School of Medicine, Thessaloniki, Greece.
Bisbinas I; 1st Department of Orthopaedics, 424 General Military Hospital, Thessaloniki, Greece.
Sakellariou GT; Department of Rheumatology, 424 General Military Hospital, Thessaloniki, Greece.
Papatheodorou A; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Kokkoris P; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Makras P; Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.

Osteoporos Int ; 26(10): 2521-7, 2015 Oct.

Article en En | MEDLINE | ID: mdl-25990355

Asunto(s)

Conservadores de la Densidad Ósea/uso terapéutico; Denosumab/uso terapéutico; Difosfonatos/uso terapéutico; Imidazoles/uso terapéutico; Osteoporosis Posmenopáusica/tratamiento farmacológico; Proteínas Adaptadoras Transductoras de Señales; Anciano; Biomarcadores/sangre; Densidad Ósea/efectos de los fármacos; Proteínas Morfogenéticas Óseas/sangre; Quimioterapia Combinada; Femenino; Marcadores Genéticos; Humanos; Vértebras Lumbares/fisiopatología; Persona de Mediana Edad; Osteoporosis Posmenopáusica/sangre; Osteoporosis Posmenopáusica/fisiopatología; Ligando RANK/sangre; Ácido Zoledrónico

Palabras clave

Bone mineral density; Bone turnover markers; Denosumab; RANKL; Sclerostin; Zoledronic acid

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteoporosis Posmenopáusica / Difosfonatos / Conservadores de la Densidad Ósea / Denosumab / Imidazoles Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Osteoporos Int Asunto de la revista: METABOLISMO / ORTOPEDIA Año: 2015 Tipo del documento: Article País de afiliación: Grecia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google